Ticker Short Interest

NMRA Short Interest Intelligence

Neumora Therapeutics, Inc. positioning pressure, squeeze risk, bearish conviction, crowding, days to cover, and price-positioning divergence.

Latest settlement 30 Jun 2026 Bearish Conviction

Bearish Conviction

Shorts Winning

NMRA is classified as Bearish Conviction. Latest reported short interest is 6.7M shares; short interest changed +35.9%, price moved -7.9% since the previous report, short interest is in the 100th percentile, and days to cover is in the 14th percentile. Trend context is weak.

Setup Score73/100Bearish Conviction
Reported Short Interest6.7M+35.9% vs prior report
Days To Cover1.1114.29 percentile
Price Reaction-7.9%since previous short report
Squeeze Pressure53crowding, trend, and pressure
Bearish Conviction73shorts adding into weakness

Reported Short Interest

2026-03-31 to 2026-06-30

Days To Cover

liquidity pressure

Short Interest Change

report-to-report

Price Context

2026-03-20 to 2026-06-26

Squeeze Radar

53

Elevated short interest becomes most interesting when price strength forces shorts to defend or cover.

Bearish Conviction

73

Rising short interest alongside weak trend can mean the bearish trade is being reinforced, not trapped.

Crowding

61

Latest short interest is 6.7M shares and days to cover is 1.11.

Divergence

0

Short interest rose while price fell. The bearish trade is currently being confirmed by price.

Report History

NMRA Short Interest Ledger

Most recent first
SettlementShort interestPreviousChangeDays coverAverage volume
30 Jun 2026 6682749 4917298 35.9% 1.11 6013588
15 Jun 2026 4917298 5581263 -11.9% 2.17 2262846
29 May 2026 5581263 4897401 14.0% 5.03 1109768
15 May 2026 4897401 4601847 6.4% 2.97 1648146
30 Apr 2026 4601847 4469003 3.0% 3.43 1343158
15 Apr 2026 4469003 4326409 3.3% 3.50 1276794
31 Mar 2026 4326409 4958521 -12.8% 4.03 1073677

Short interest is delayed, reported on a periodic schedule, and may be revised. The dashboard is research context only and does not prove real-time short activity.